neuritis |
Disease ID | 1359 |
---|---|
Disease | neuritis |
Manually Symptom | (Waiting for update.) |
Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:2) |
Manually Genotype(Total Text Mining Genotypes:0) |
---|
(Waiting for update.) |
All Snps(Total Genotypes:0) | |
---|---|
(Waiting for update.) |
GWASdb Annotation(Total Genotypes:0) | |
---|---|
(Waiting for update.) |
GWASdb Snp Trait(Total Genotypes:0) | |
---|---|
(Waiting for update.) |
Mapped by lexical matching(Total Items:0) |
---|
(Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
---|
(Waiting for update.) |
Chemical(Total Drugs:9) | |||||||||
---|---|---|---|---|---|---|---|---|---|
CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
C0027813 | fluorouracil | D005472 | 51-21-8 | neuritis | MESH:D009443 | marker/mechanism | 17430663 | ||
C0027813 | leucovorin | D002955 | 1958/5/9 | neuritis | MESH:D009443 | marker/mechanism | 17430663 | ||
C0027813 | foscarnet | D017245 | 4428-95-9 | neuritis | MESH:D009443 | marker/mechanism | 9761526 | ||
C0027813 | lidocaine | D008012 | 137-58-6 | neuritis | MESH:D009443 | marker/mechanism | 19224819 | ||
C0027813 | oxaliplatin | C030110 | - | neuritis | MESH:D009443 | marker/mechanism | 17430663 | ||
C0027813 | paclitaxel | D017239 | - | neuritis | MESH:D009443 | marker/mechanism | 8893892 | ||
C0027813 | thalidomide | D013792 | 50-35-1 | neuritis | MESH:D009443 | marker/mechanism | 7579470 | ||
C0027813 | vinblastine | D014747 | 865-21-4 | neuritis | MESH:D009443 | marker/mechanism | 5768441 | ||
C0027813 | vinorelbine | C030852 | 71486-22-1 | neuritis | MESH:D009443 | marker/mechanism | 18819904 |
FDA approved drug and dosage information(Total Drugs:3) | ||||||||
---|---|---|---|---|---|---|---|---|
DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
MESH:D009443 | eloxatin | oxaliplatin | 50MG/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons | INJECTABLE;IV (INFUSION) | Discontinued | None | Yes | No |
MESH:D009443 | eloxatin | oxaliplatin | 50MG/10ML (5MG/ML) | INJECTABLE;IV (INFUSION) | Prescription | AP | Yes | Yes |
MESH:D009443 | oxaliplatin | oxaliplatin | 50MG/10ML (5MG/ML) | INJECTABLE;IV (INFUSION) | Prescription | AP | Yes | Yes |
FDA labeling changes(Total Drugs:3) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
MESH:D009443 | 10/1/2007 | eloxatin | oxaliplatin | Solid tumors | The effectiveness of oxaliplatin in children has not been established No significant activity observed in 2 Phase I and 2 Phase II trials in 159 patients ages 7 months to 22 years with solid tumors Information on clinical studies and AEs | Labeling | B | - | - | - | Sanofi-Aventis | 09/27/2006 | FALSE' |
MESH:D009443 | 10/1/2007 | eloxatin | oxaliplatin | Solid tumors | The effectiveness of oxaliplatin in children has not been established No significant activity observed in 2 Phase I and 2 Phase II trials in 159 patients ages 7 months to 22 years with solid tumors Information on clinical studies and AEs | Labeling | B | - | - | - | Sanofi-Aventis | 09/27/2006 | FALSE' |
MESH:D009443 | 10/1/2007 | eloxatin | oxaliplatin | Solid tumors | The effectiveness of oxaliplatin in children has not been established No significant activity observed in 2 Phase I and 2 Phase II trials in 159 patients ages 7 months to 22 years with solid tumors Information on clinical studies and AEs | Labeling | B | - | - | - | Sanofi-Aventis | 09/27/2006 | FALSE' |